Gisslén M - Search Results

1

Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.

Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JL, Chalermchai T, Krebs SJ, Robb ML, Hellmuth J, Gisslén M, Zetterberg H, Spudich S; RV254SEARCH 010, RV304SEARCH 013, and SEARCH 011 Study Teams. Peluso MJ, et al. Among authors: gisslen m. AIDS. 2017 Jan 14;31(2):247-252. doi: 10.1097/QAD.0000000000001314. AIDS. 2017. PMID: 27819802 Free PMC article.

2

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Abdulle S, et al. Among authors: gisslen m. AIDS. 2002 Nov 8;16(16):2145-9. doi: 10.1097/00002030-200211080-00006. AIDS. 2002. PMID: 12409735

3

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L. Arvidson N, et al. Among authors: gisslen m. AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5. doi: 10.1089/0889222041524625. AIDS Res Hum Retroviruses. 2004. PMID: 15307916

4

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. Scand J Infect Dis. 2004;36(11-12):823-8. doi: 10.1080/00365540410025320. Scand J Infect Dis. 2004. PMID: 15764168 Clinical Trial.

5

Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cinque P, et al. Among authors: gisslen m. J Neuroimmunol. 2005 Nov;168(1-2):154-63. doi: 10.1016/j.jneuroim.2005.07.002. Epub 2005 Aug 8. J Neuroimmunol. 2005. PMID: 16091292

6

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M. Mellgren A, et al. Among authors: gisslen m. Antivir Ther. 2005;10(6):701-7. Antivir Ther. 2005. PMID: 16218168 Clinical Trial.

7

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73. doi: 10.1097/QAI.0b013e31815ace97. J Acquir Immune Defic Syndr. 2008. PMID: 17971711 Free PMC article.

8

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.

Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Gisslen M, et al. J Neuroimmune Pharmacol. 2007 Mar;2(1):112-9. doi: 10.1007/s11481-006-9035-1. Epub 2006 Sep 12. J Neuroimmune Pharmacol. 2007. PMID: 18040834 Review.

9

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Edén A, et al. Among authors: gisslen m. J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648. J Infect Dis. 2007. PMID: 18190258

10

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61. doi: 10.1089/aid.2008.0216. AIDS Res Hum Retroviruses. 2009. PMID: 19320601 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

314 results

Search Page

Filters